AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21306210 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision-making based on biomarkers
Number of subjects: 0
Study 21306793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring with vagal nerve stimulation
Number of subjects: 390
Study 21306793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring
Number of subjects: 390
Study 21308151 — intervention group
Group type: EXPERIMENTAL
Intervention: Givinostat (ITF 2357), an orally active HDAC inhibitor, administered for 12 weeks.
Number of subjects: 0
Study 21308151 — intervention group
Group type: COMPARATOR
Intervention: Control not specified, but implied comparison to standard treatments like methotrexate and anticytokines.
Number of subjects: 0
Study 21310317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1820
Study 21310379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear osmolarity
Number of subjects: 314
Study 21310379 — intervention group
Group type: COMPARATOR
Intervention: Corneal staining
Number of subjects: 314
Study 21310379 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival staining
Number of subjects: 314
Study 21310379 — intervention group
Group type: COMPARATOR
Intervention: Meibomian gland grading
Number of subjects: 314
Study 21310379 — intervention group
Group type: COMPARATOR
Intervention: Tear film break-up time
Number of subjects: 314
Study 21310379 — intervention group
Group type: COMPARATOR
Intervention: Schirmer test
Number of subjects: 314
Study 21310866 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation with pyridoxine hydrochloride (40 mg/d) for 1 month
Number of subjects: 3035
Study 21310866 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma PLP
Number of subjects: 3035
Study 21310912 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse-trickling GA phenotype
Number of subjects: 36
Study 21310912 — intervention group
Group type: COMPARATOR
Intervention: Non diffuse-trickling GA
Number of subjects: 36
Study 21311383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Magnesium Sulphate
Number of subjects: 0
Study 21311694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMMC) infusion after granulocyte colony-stimulating factor administration.
Number of subjects: 0
Study 21311694 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC cell therapy
Number of subjects: 0
Study 21311985 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial radiofrequency surgery of the soft palate (single session)
Number of subjects: 74
Study 21314962 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy
Number of subjects: 0
Study 21317257 — intervention group
Group type: EXPERIMENTAL
Intervention: O157 STEC strains
Number of subjects: 51
Study 21317257 — intervention group
Group type: EXPERIMENTAL
Intervention: non-O157 STEC strains
Number of subjects: 51
Study 21317257 — intervention group
Group type: EXPERIMENTAL
Intervention: non-O157 biofilm-producing isolates
Number of subjects: 51
Study 21317257 — intervention group
Group type: EXPERIMENTAL
Intervention: O157 strains
Number of subjects: 51
Study 21317257 — intervention group
Group type: EXPERIMENTAL
Intervention: non-O157 strains
Number of subjects: 51
Study 21317503 — intervention group
Group type: EXPERIMENTAL
Intervention: Various recruitment strategies
Number of subjects: 45
Study 21317503 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives and follow-up mechanisms
Number of subjects: 45
Study 21319147 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level intervention (patient decision aid and stage-targeted brochures mailed to members)
Number of subjects: 443
Study 21319147 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 443
Study 21319147 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level intervention (adjusted for baseline differences)
Number of subjects: 443
Study 21319147 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level intervention (for participants with incomes >$50,000)
Number of subjects: 443
Study 21319147 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level intervention (for participants with lower incomes)
Number of subjects: 443
Study 21320355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab and IMRT/carbon ion boost (18 GyE carbon ions in 6 fractions and 54 Gy IMRT at 2.0 Gy/fraction)
Number of subjects: 49
Study 21320355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 49
Study 21320979 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-inflammatory treatment
Number of subjects: 0
Study 21321062 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (1 mg/d) for 8 weeks
Number of subjects: 10
Study 21321062 — intervention group
Group type: EXPERIMENTAL
Intervention: Low folate diet for 12 weeks followed by folic acid repletion (1 mg/d) for 4 weeks
Number of subjects: 10
Study 21324375 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of AS03-adjuvanted H1N1 influenza vaccine
Number of subjects: 17
Study 21324375 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of AS03-adjuvanted H1N1 influenza vaccine
Number of subjects: 17
Study 21325343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25[OH]D < 20 ng/mL)
Number of subjects: 368
Study 21325343 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals who were vitamin D deficient at baseline but no longer deficient at follow-up
Number of subjects: 368
Study 21325343 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in 25(OH)D to greater than or equal to 20 ng/mL
Number of subjects: 368
Study 21328719 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (first generation antipsychotic)
Number of subjects: 60
Study 21328719 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (second generation antipsychotic)
Number of subjects: 60
Study 21328719 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 60
Study 21328719 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 60
Study 21328719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study 21329725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir discontinuation
Number of subjects: 0
Study 21330384 — intervention group
Group type: EXPERIMENTAL
Intervention: Better septal function
Number of subjects: 917
Study 21330384 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal strain from -18% to -10%
Number of subjects: 917
Study 21330384 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal function
Number of subjects: 917
Study 21330384 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventricular septal function
Number of subjects: 917
Study 21330400 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization of continuous variables
Number of subjects: 0
Study 21330400 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of data-derived 'optimal' cut-points
Number of subjects: 0
Study 21330400 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of results from a registry on unruptured intracranial aneurysms
Number of subjects: 0
Study 21330400 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous explanatory variables
Number of subjects: 0
Study 21330601 — intervention group
Group type: EXPERIMENTAL
Intervention: mCSCs isolated from endomyocardial biopsies
Number of subjects: 0
Study 21330601 — intervention group
Group type: EXPERIMENTAL
Intervention: vCSCs isolated from endomyocardial biopsies
Number of subjects: 0
Study 21330601 — intervention group
Group type: COMPARATOR
Intervention: mCSCs and vCSCs isolated from endomyocardial biopsies
Number of subjects: 0
Study 21330625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment no dementia (CIND)
Number of subjects: 419
Study 21330625 — intervention group
Group type: EXPERIMENTAL
Intervention: CIND-mild and CIND-moderate
Number of subjects: 419
Study 21330625 — intervention group
Group type: EXPERIMENTAL
Intervention: CIND-moderate
Number of subjects: 419
Study 21330625 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuomotor speed impairment
Number of subjects: 419
Study 21330625 — intervention group
Group type: EXPERIMENTAL
Intervention: CIND severity
Number of subjects: 419
Study 21330625 — intervention group
Group type: COMPARATOR
Intervention: No independent predictors
Number of subjects: 419
Study 21330656 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A (eye tracker and retest function engaged)
Number of subjects: 103
Study 21330656 — intervention group
Group type: COMPARATOR
Intervention: Method B (without eye tracker and retest function)
Number of subjects: 103
Study 21333027 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative health care model (IHCM) involving a family doctor, nurse, psychologist, and the woman herself, lasting three months with a three-month follow-up period.
Number of subjects: 0
Study 21333082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) program for 6 weeks
Number of subjects: 0
Study 21334018 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity focused ultrasound hemiablation
Number of subjects: 20
Study 21334404 — intervention group
Group type: EXPERIMENTAL
Intervention: rs738409 polymorphism in ALD patients
Number of subjects: 330
Study 21334404 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 mRNA liver expression level in ALD patients
Number of subjects: 330
Study 21334562 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiscriminately social/disinhibited RAD
Number of subjects: 129
Study 21334562 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally withdrawn/inhibited RAD
Number of subjects: 129
Study 21334595 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab injected monthly for one year
Number of subjects: 10
Study 21338429 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma subjects (smokers, ex-smokers, never-smokers)
Number of subjects: 59
Study 21338429 — intervention group
Group type: COMPARATOR
Intervention: Normal smokers
Number of subjects: 59
Study 21338641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg/d) plus metronomic tegafur/uracil (250 mg/m(2)/d)
Number of subjects: 31
Study 21338641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus tegafur/uracil
Number of subjects: 31
Study 21338641 — intervention group
Group type: EXPERIMENTAL
Intervention: K(trans) change after treatment
Number of subjects: 31
Study 21339701 — intervention group
Group type: EXPERIMENTAL
Intervention: Menveo® (MenACWY-CRM; Novartis)
Number of subjects: 0
Study 21339701 — intervention group
Group type: COMPARATOR
Intervention: Menactra® (MCV4; sanofi pasteur)
Number of subjects: 0
Study 21342518 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing sedentary behaviors by 25%
Number of subjects: 55
Study 21342518 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing sedentary behaviors by 50%
Number of subjects: 55
Study 21342518 — intervention group
Group type: COMPARATOR
Intervention: Baseline sedentary behavior
Number of subjects: 55
Study 21342518 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing sedentary behaviors
Number of subjects: 55
Study 21343560 — intervention group
Group type: EXPERIMENTAL
Intervention: RUNX1 mutations
Number of subjects: 945
Study 21343560 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem-cell transplantation
Number of subjects: 945
Study 21343760 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple marker test using four markers (progesterone, VEGF, inhibin A, activin A)
Number of subjects: 200
Study 21343760 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual biomarkers (inhibin A, progesterone, activin A, VEGF, pregnancy-specific β-1-glycoprotein, pregnancy-associated plasma protein-A)
Number of subjects: 200
Study 21343760 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional six markers
Number of subjects: 200
Study 21344317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmented QRS (fQRS) at the 48th hour after primary PCI (group 1)
Number of subjects: 85
Study 21344317 — intervention group
Group type: COMPARATOR
Intervention: No fragmented QRS (group 2)
Number of subjects: 85
Study 21344317 — intervention group
Group type: EXPERIMENTAL
Intervention: fQRS
Number of subjects: 85
Study 21344317 — intervention group
Group type: EXPERIMENTAL
Intervention: Q wave
Number of subjects: 85
Study 21344317 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS distortion
Number of subjects: 85
Study 21344317 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of chest pain
Number of subjects: 85
Study 21344317 — intervention group
Group type: EXPERIMENTAL
Intervention: fQRS at 48th hour
Number of subjects: 85
Study 21344495 — intervention group
Group type: EXPERIMENTAL
Intervention: PFDI short form
Number of subjects: 1006
Study 21344495 — intervention group
Group type: EXPERIMENTAL
Intervention: PFIQ short form
Number of subjects: 1006
Study 21344495 — intervention group
Group type: EXPERIMENTAL
Intervention: PFDI-20 urinary scale
Number of subjects: 1006
Study 21344495 — intervention group
Group type: EXPERIMENTAL
Intervention: PFDI-20 prolapse scale
Number of subjects: 1006
Study 21344495 — intervention group
Group type: EXPERIMENTAL
Intervention: PFDI-20 colorectal scale
Number of subjects: 1006
Study 21344495 — intervention group
Group type: EXPERIMENTAL
Intervention: PFIQ-7 scales
Number of subjects: 1006
Study 21344495 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 (or SF-12) summary scores
Number of subjects: 1006
Study 21345642 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-seronegative plus leukoreduced blood products
Number of subjects: 1300
Study 21345726 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg) and Bortezomib (1.6 mg/m2)
Number of subjects: 63
Study 21346617 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study 21349464 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 3388
Study 21349999 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib (800 mg orally once daily)
Number of subjects: 55
Study 21350030 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision total hip arthroplasty (THA) with acetabular bone impaction grafting
Number of subjects: 20
Study 21350030 — intervention group
Group type: COMPARATOR
Intervention: Primary total hip arthroplasty (THA)
Number of subjects: 20
Study 21350210 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial aortic occlusion after thrombolysis
Number of subjects: 22
Study 21352516 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-enabled mobile phone intervention with daily online entries and individualized written feedback
Number of subjects: 6
Study 21352516 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-enabled mobile phone intervention
Number of subjects: 6
Study 21352561 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera®) combined with involved field radiotherapy (30 - 40 Gy)
Number of subjects: 85
Study 21352601 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg orally administered AS (artesunate)
Number of subjects: 51
Study 21354816 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic tracking and multimodality image fusion guidance for biopsy and RF ablation procedures
Number of subjects: 40
Study 21355002 — intervention group
Group type: EXPERIMENTAL
Intervention: Belotecan (CKD 602) at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Number of subjects: 16
Study 21355077 — intervention group
Group type: EXPERIMENTAL
Intervention: Langerhans cell (LC) vaccines
Number of subjects: 0
Study 21355077 — intervention group
Group type: COMPARATOR
Intervention: monocyte-derived dendritic cell (moDC) vaccines
Number of subjects: 0
Study 21355087 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 25 mg/m(2), vinblastine 6 mg/m(2), and gemcitabine 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days for 6 cycles
Number of subjects: 99
Study 21355087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle 2 PET-negative patients
Number of subjects: 99
Study 21355087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle 2 PET-positive patients
Number of subjects: 99
Study 21355087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle 6 PET-negative patients
Number of subjects: 99
Study 21355087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle 6 PET-positive patients
Number of subjects: 99
Study 21355097 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin (depsipeptide or FK228), a histone deacetylase inhibitor
Number of subjects: 47
Study 21355097 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study 21355725 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy (Animas(®) 2020, Animas Corp.) for 16 weeks
Number of subjects: 54
Study 21356058 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 9967
Study 21356058 — intervention group
Group type: COMPARATOR
Intervention: Other gastrointestinal drugs (except PPIs)
Number of subjects: 9967
Study 21356079 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 2 mg/kg subcutaneously (s.c.) for patients with body weight ≤ 40 kg or 150 mg s.c. for patients with body weight > 40 kg.
Number of subjects: 7
Study 21356124 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) 0.5 mg/kg normal body weight/day, injected subcutaneously for 14 days, followed by a break of one week, repeated to a maximum of nine times.
Number of subjects: 20
Study 21356124 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) treatment in 12 patients who completed all nine cycles.
Number of subjects: 20
Study 21356124 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) treatment in 20 patients.
Number of subjects: 20
Study 21357363 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 21357390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment
Number of subjects: 18
Study 21357403 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-1
Number of subjects: 8
Study 21357403 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-3
Number of subjects: 8
Study 21357403 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostaining of MMP-1 and -3
Number of subjects: 8
Study 21357403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured conjunctival fibroblasts
Number of subjects: 8
Study 21357403 — intervention group
Group type: COMPARATOR
Intervention: MMP-2 and TIMP-1 and -2
Number of subjects: 8
Study 21357403 — intervention group
Group type: COMPARATOR
Intervention: MMP-9
Number of subjects: 8
Study 21357404 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC-treated off-flap
Number of subjects: 93
Study 21357404 — intervention group
Group type: COMPARATOR
Intervention: MMC-treated on-flap
Number of subjects: 93
Study 21357404 — intervention group
Group type: COMPARATOR
Intervention: Non-MMC treated on-flap
Number of subjects: 93
Study 21357404 — intervention group
Group type: COMPARATOR
Intervention: Non-MMC treated off-flap
Number of subjects: 93
Study 21357404 — intervention group
Group type: EXPERIMENTAL
Intervention: on-flap
Number of subjects: 93
Study 21357404 — intervention group
Group type: EXPERIMENTAL
Intervention: off-flap
Number of subjects: 93
Study 21358295 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1,250 mg/m² twice daily for 14 days, followed by 14 days of rest)
Number of subjects: 51
Study 21358295 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 51
Study 21358414 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral renal denervation via percutaneous endovascular radiofrequency ablation
Number of subjects: 2
Study 21358415 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham risk score (FRS) at 1 year
Number of subjects: 6460
Study 21358415 — intervention group
Group type: EXPERIMENTAL
Intervention: UACR (urine albumin/creatinine ratio) at baseline
Number of subjects: 6460
Study 21358415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sokolow-Lyon (left ventricular hypertrophy) at baseline
Number of subjects: 6460
Study 21358415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell product (1 year)
Number of subjects: 6460
Study 21358415 — intervention group
Group type: EXPERIMENTAL
Intervention: UACR (1 year)
Number of subjects: 6460
Study 21358415 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of left ventricular hypertrophy by Cornell product (1 year) or UACR (1 year) at least 1 mmol/l
Number of subjects: 6460
Study 21358415 — intervention group
Group type: EXPERIMENTAL
Intervention: FRS (1 year) above the median baseline value of 20
Number of subjects: 6460
Study 21358415 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD (subclinical organ damage) (1 year)
Number of subjects: 6460
Study 21358415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell product (1 year) and UACR (1 year)
Number of subjects: 6460
Study 21359089 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption prior to polysomnography
Number of subjects: 958
Study 21359089 — intervention group
Group type: COMPARATOR
Intervention: No caffeine consumption prior to polysomnography
Number of subjects: 958
Study 21359193 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine deficiency (mean urinary iodine excretion, 49.8 µg/L)
Number of subjects: 110
Study 21359193 — intervention group
Group type: COMPARATOR
Intervention: Normal iodine levels (not explicitly mentioned in the abstract)
Number of subjects: 110
Study 21359517 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 45
Study 21359517 — intervention group
Group type: EXPERIMENTAL
Intervention: QCA
Number of subjects: 45
Study 21359517 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS
Number of subjects: 45
Study 21359517 — intervention group
Group type: COMPARATOR
Intervention: IVUS-OCT
Number of subjects: 45
Study 21359517 — intervention group
Group type: COMPARATOR
Intervention: Videodensitometry-IVUS
Number of subjects: 45
Study 21359953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,000 mg/day and nab-paclitaxel 260 mg/m2 every 3 weeks for four cycles
Number of subjects: 30
Study 21360250 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green adsorbed to human serum albumin (ICG:HSA) at concentrations from 50 to 1000 μM, injected after patent blue.
Number of subjects: 24